About IAVI
IAVI is a Government & Social Sector company based in New York (United States) founded in 1996. IAVI is focused on developing vaccines and antibodies for infectious diseases. It operates on a Donation / Grant-Based model. Its chief executive, as recorded, is Mark Feinberg. Its website iavi.org draws about 28 thousand monthly visits. Its Indian entity Iavi India reported revenue of ₹71.4 Lakh. IAVI offers products and services including HIV Vaccines, HIV Antibodies, Tuberculosis Vaccines, Lassa Virus Vaccine, and Marburg Virus Vaccine. Its focus areas include Healthcare, Biotechnology and Vaccine Development.
Company details
IAVI, a nonprofit scientific research organization, is dedicated to the development of vaccines and antibodies targeting HIV, tuberculosis, and emerging infectious diseases such as Lassa, Marburg, and Sudan viruses. Research and development efforts are conducted across global hubs in Africa, Europe, India, and the United States. Solutions are advanced through preclinical and clinical trials, with a full-circle approach from grassroots to legislative advocacy. Collaboration with academic, biotech, and global health partners is emphasized to ensure affordable and accessible public health solutions. Policy and community engagement initiatives are also pursued to support vaccine access in high-need regions.
- Indian entity revenue₹71.4 Lakh
FY 2017
- Indian entity net loss-₹32,787
FY 2017 · 0% margin
- Indian entity EBITDA-₹71.4 Lakh
FY 2017 · -100% margin
- Latest Funding Round$143.32M (USD), Grant
May 2022
- InvestorsHHS
& 4 more
Associated legal entities of IAVI
IAVI operates through Iavi India (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2017) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Iavi India CIN U73100HR2013NPL105309 | Active | 27 Nov 2013 | Gurgaon, Haryana | ₹0.7 Cr | 2 | View details |
Products & Services of IAVI
IAVI offers a comprehensive portfolio of products and services, including HIV Vaccines, HIV Antibodies, Tuberculosis Vaccines, Lassa Virus Vaccine, and Marburg Virus Vaccine.
HIV vaccines are developed to prevent HIV acquisition.
HIV antibodies are researched to combat HIV infection.
TB vaccines are advanced for global health protection.
Lassa vaccine is developed for West African outbreaks.
Marburg vaccine is created to address deadly outbreaks.
Apps and channels of IAVI
its YouTube channel IAVI has 946K subscribers and 30 videos.
Videos from IAVI
The most watched videos on IAVI's YouTube channel, IAVI (946K subscribers). Click a video to play it here.
More on IAVI.
Funding Insights of IAVI
- Total Rounds 10
- Last Round Grant — $143.32M
- First Round $143.32M
(Aug 2006)
- Investors Count 5
All 10 funding rounds of IAVI with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2022 | $143.32M | Grant | – | – | |
| Nov 2021 | $184,016 | Grant | – | – | |
| Jun 2021 | $27.61M | Grant | – | – | |
| Jul 2016 | $12.21M | Grant | – | – | |
| Feb 2012 | $138.71M | Grant | – | – | |
| Jul 2011 | $69,906 | Grant | – | – | |
| Nov 2010 | $138.71M | Grant | – | – | |
| Sep 2009 | $2.03M | Grant | – | – | |
| Sep 2009 | $2.03M | Grant | – | – | |
| Aug 2006 | $143.32M | Grant | – | – |
5 investors in total: 5 institutional.
Investors in IAVI
IAVI has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, USAID and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare investments are targeted by this private equity firm. | 2017 | cepi.net | Oslo, Norway | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Company provides funding for clinical research on infectious diseases | 2003 | edctp.org | The Hague, Netherlands | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Global poverty and development are addressed through USAID initiatives. | 1961 | usaid.gov |
Investor details for IAVI
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Iavi India (IAVI)
Iavi India is the primary company behind IAVI. The board of Iavi India currently have 2 directors; the longest-serving is Sandeep Mathur, appointed in 2013.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sandeep Mathur DIN 03502264 | Director | 27 Nov 2013 | 12 yrs 11 mo | Iavi India |
| Rajat Goyal DIN 03192623 | Director | 27 Nov 2013 | 12 yrs 11 mo | Iavi India |
People of IAVI
45 people are tracked at IAVI (39 in leadership, 6 in team).
| Name | Role | Group |
|---|---|---|
Mark Feinberg | CEO & President | Leadership |
Sandip Patel | Associate Director, CMC Development | Leadership |
Dhurata Dono | Associate Director, Product Development And CMC | Leadership |
Jennifer Lehrman | Sr. Director, Clinical Alliances | Leadership |
Ansuya Naidoo | Senior Director Product Development Team Lead | Leadership |
Benjamin Blum | Director, Data Science And Bioinformatics | Leadership |
Rose Catlos | Director Of Communications | Leadership |
George Amemba | Director - Risk, Audit & Compliance | Leadership |
Kara Bickham | Chief Development Officer (cdo) | Leadership |
Sam Pallerla | Senior Director, Product Development And Manufacturing | Leadership |
Godfrey Branch | Sr. Director Of Information Technology | Leadership |
Gwynneth Stevens | Director Laboratory Program | Leadership |
Sree Chitoor | Chief Technology Officer | Leadership |
Laurie Johnson | Director Data Management | Leadership |
Nuno Viegas | Director Of Scientific Affairs, Alliances And Fundraising | Leadership |
Stephen Baker | Executive Director, Human Immunology Laboratory | Leadership |
Sangeetha Sagar | Vice President, Product Development | Leadership |
Jon Heinrichs | Vice President, Antibody Program Strategy And Translational Immunology | Leadership |
Mario Gagliano | Vice President, Human Resources & Chief People Officer | Leadership |
Saif Ul Hadi | Director – Global Access, Policy & Behavioral Research | Leadership |
25 more people are available in the full profile.
Complete people profiles for IAVI
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of IAVI
Figures of Iavi India, the primary company behind IAVI, for FY 2017. Revenue was ₹71.4 Lakh. Net loss was -₹32,787 (0% margin). EBITDA was -₹71.4 Lakh (-100% margin).
- ₹71.4 LakhRevenue · FY 2017
- -₹32,787Net loss · 0% margin
- -₹71.4 LakhEBITDA · -100% margin
- ₹1 LakhPaid-up capital
Balance sheet, profit and loss, cash flow and ratios of Iavi India are on its company page.
Detailed financial statements for IAVI
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of IAVI
3 dated milestones of IAVI across 26 years, from founding to its latest funding, stage changes and deals.
- Founded IAVI is founded.
- Funding First funding round of $143.3M.
- Funding Latest funding round, Grant, of $143.3M.
Web traffic of IAVI
The website of IAVI (iavi.org) receives about 27.5K visits a month.
- Monthly visits27.5K
▼ 13.9% vs previous month
Websites whose visitors overlap most with IAVI. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| aidsportal.org | 100% | View details | |||
latesthivtreatment.org | latesthivtreatment.org | 84% | – | ||
| thewellproject.org | 84% | #502,982 | View details | ||
| vaccineenterprise.org | 84% | View details | |||
dignitasinternational.org | dignitasinternational.org | 83% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 36 similar websites and full traffic analytics for IAVI
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 36 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Foundations
3 companies that operate in the same segment as IAVI (Foundations) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Humanitarian services are provided by UNICEF in developing countries. | 1946 | United States | ||||
Research institute for improving the human condition by turning knowledge into practice | 1958 | United States | USD 7.84 M | 92 | ||
Poverty eradication efforts are coordinated by Global Citizen foundation. | 2008 | New York, New York, United States | USD 35 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about IAVI
IAVI was founded in 1996 and raised its 1st funding round 10 years after it was founded.
IAVI is headquartered in New York, United States. It is registered at New York, New York, United States.
Mark Feinberg is the CEO of IAVI, as recorded in our data.
The primary company behind IAVI, Iavi India, reported revenue of ₹71.4 Lakh for FY 2017.
IAVI, a nonprofit scientific research organization, is dedicated to the development of vaccines and antibodies targeting HIV, tuberculosis, and emerging infectious diseases such as Lassa, Marburg, and Sudan viruses. Research and development efforts are conducted across global hubs in Africa, Europe, India, and the United States. Solutions are advanced through preclinical and clinical trials, with a full-circle approach from grassroots to legislative advocacy. Collaboration with academic, biotech, and global health partners is emphasized to ensure affordable and accessible public health solutions. Policy and community engagement initiatives are also pursued to support vaccine access in high-need regions.
IAVI offers HIV Vaccines, HIV Antibodies, Tuberculosis Vaccines, Lassa Virus Vaccine, and Marburg Virus Vaccine.
IAVI has 5 investors. Key investors include HHS, USAID, European Union, CEPI, and EDCTP.
IAVI operates through Iavi India.
The legal entities of IAVI currently have 2 directors, including Sandeep Mathur, Rajat Goyal.